Utah Medical Products Inc. has reported its financial results for the third quarter of 2026, revealing a significant decline in revenue. This downturn is primarily attributed to the loss of two major customers, which has raised concerns about the company's ability to maintain its market position in the surgical and medical instruments industry.
In the filing dated October 22, 2026, Utah Medical Products, which trades on Nasdaq under the ticker UTMD, detailed its financial performance for the three and nine months ended September 30, 2026. The company operates in the Surgical & Medical Instruments & Apparatus sector, classified under SIC 3841.
According to the filing, the company’s revenues for the third quarter fell by 12.1% compared to the same period in 2025, with total revenues reported at $1,191,000. For the first nine months of 2026, revenues also declined by 12.1%, totaling $3,602,000. This decline was significantly influenced by the absence of sales to its two largest customers from the previous year, PendoTECH and a distributor of blood pressure monitoring kits in China.
The filing states, "The lower sales in comparison with the prior year's periods were substantially a result of a lack of any 2026 sales to UTMD's two previously largest customers." This loss has not only impacted revenue but has also raised questions about the company’s future sales strategies and customer retention efforts.
Despite the setbacks, Utah Medical Products reported some positive developments. The company has begun to generate sales from new biopharmaceutical customers, although this growth has been slower than anticipated. In Q3 2026, the company realized $116,000 in sales from these new customers, and $195,000 from a new distributor in China.
Additionally, the company’s subsidiary, Femcare Ltd, acquired Orion Medical Supplies Ltd in the UK, which contributed $619,000 in sales for the third quarter. This acquisition may provide a strategic advantage as Utah Medical Products seeks to stabilize and grow its revenue streams.
However, the overall market for the company’s Filshie Clip System has seen a decline, with sales dropping by 32.7% in Q3 2026 compared to the previous year. This decline has raised concerns about the company’s product competitiveness and market adaptability.
Looking ahead, the company plans to address these challenges through strategic initiatives aimed at regaining lost customers and expanding its market presence. Further details on these strategies are expected to be discussed in the upcoming SEC 10-Q disclosure scheduled for November.
As the surgical and medical instruments industry continues to evolve, Utah Medical Products Inc. faces the dual challenge of recovering from recent losses while also adapting to new market conditions. The company’s ability to navigate these challenges will be crucial in determining its future performance and competitiveness in the sector.